Open-Labeled Trial Of Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 05 Dec 2018
At a glance
- Drugs Elbasvir/grazoprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms USHER
- 27 Nov 2018 Planned End Date changed from 1 Aug 2019 to 1 Dec 2020.
- 27 Nov 2018 Planned primary completion date changed from 1 Jun 2019 to 1 Dec 2019.
- 27 Nov 2018 Status changed from recruiting to active, no longer recruiting.